Role of Bone-modifying Agents in Multiple Myeloma (beta)
Based on guidelines from the American Society of Clinical Oncology.
For patients with multiple myeloma who, on plain radiograph(s) or other imaging studies (MRI or CT scan), have lytic destruction of the bone or compression fracture of the spine from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes every 3 to 4 weeks is recommended. Alternative treatment includes the use of denosumab, a monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand.
Intravenous pamidronate or zoledronic acid is recommended for patients with pain as a result of osteolytic disease and as an adjunctive treatment of patients receiving radiation therapy, analgesics, or surgical intervention to stabilize fractures or impending fractures. Denosumab is an additional option.
As a result of increased concerns over renal adverse events, dosing guidelines for patients with preexisting renal impairment were added to the zoledronic acid package insert. Guidelines recommend that patients with preexisting mild-to-moderate renal impairment—estimated creatinine clearance, 30 to 60 mL/min—should receive a reduced dosage of zoledronic acid. No changes in infusion time or interval are required. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended for use in these patients. Recent data that compare denosumab with zoledronic acid has demonstrated fewer adverse events related to renal toxicity with denosumab, and this may be preferred in patients with compromised renal function.
Pamidronate 90 mg administered over 4 to 6 hours is recommended for patients with extensive bone disease and existing severe renal impairment—serum creatinine level >3.0 mg/dL (265 µmol/L) or an estimated creatinine clearance of <30 mL/min. Although no dosing guidelines are available for patients with preexisting renal impairment, the Expert Panel recommends that clinicians consider reducing the initial pamidronate dose in that setting. Infusion times <2 hours with pamidronate or <15 minutes with zoledronic acid should be avoided.
The Expert Panel suggests that bone-targeting treatment continue for a period of up to 2 years. Less-frequent dosing has been evaluated and should be considered in patients with responsive or stable disease. In patients who do not have active myeloma and are on maintenance therapy, the physician may consider a 3-month interval of bisphosphonate administration. There are no data to support a more precise recommendation for the duration of bisphosphonate therapy in this group of patients. For those patients for whom bisphosphonates were withdrawn after 2 years, the drug should be resumed upon relapse with new-onset skeletal-related events. Denosumab should not be stopped abruptly, given its reversible mechanism of action.
The Expert Panel recommends that serum creatinine should be monitored before each dose of pamidronate or zoledronic acid, in accordance with U.S. Food and Drug Administration (FDA)–approved labeling. Denosumab does not require monitoring of renal function.
In patients who develop renal deterioration without an apparent cause during bisphosphonate therapy, zoledronic acid or pamidronate should be withheld. Bisphosphonate therapy can be resumed at the same dosage as that before treatment interruption, when serum creatinine returns to within 10% of the baseline level. Denosumab requires no dose modification.
Serum calcium should be monitored regularly, and serum vitamin D levels should be evaluated intermittently. Hypocalcemia is an adverse effect of all bone resorptive agents and is more pronounced with denosumab. Patients should be calcium and vitamin D repleted.
The Expert Panel also recommends intermittent evaluation—every 3 to 6 months—of all patients receiving pamidronate or zoledronic acid therapy for the presence of albuminuria on a spot urine sample. In patients who experience unexplained albuminuria, a 24-hour urine collection should be obtained to assess for >500 mg/24 hours of urinary albumin, and discontinuation of the drug is advised until renal problems are resolved. These patients should be reassessed every 3 to 4 weeks—with a 24-hour urine collection for total protein and urine protein electrophoresis—and pamidronate should be reinstituted over a longer infusion time (≥4 hours) and at doses not to exceed 90 mg every 4 weeks when renal function returns to baseline.
The Expert Panel supports the use of screening urinalysis for proteinuria, but underscores that a 24-hour urine collection for the determination of total protein and electrophoresis is required if the test is positive. Although no similar guidelines are available for zoledronic acid, some Expert Panel members recommend that zoledronic acid be reinstituted over a longer infusion time (≥30 minutes).
Osteonecrosis of the jaw (ONJ) is an uncommon but potentially serious complication of intravenous bisphosphonates and denosumab. The Expert Panel agrees with the recommendations described in the revised FDA label for zoledronic acid and pamidronate, Dear Doctor letters, a white paper, and various position papers or statements. All patients should receive a comprehensive dental examination and appropriate preventive dentistry before bone-modifying therapy. Active oral infections should be treated, and sites that are at high risk for infection should be eliminated. While on therapy, patients should maintain excellent oral hygiene and avoid invasive dental procedures, if possible. Continuation of a bone-targeting agent in the setting of ONJ has to be individualized and dependent on a risk–benefit ratio and the severity of bone disease.
How strong is the ASCO's recommendation?